These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 23678600)

  • 1. [Aripiprazole as "dopamine sensitivity stabilizer"].
    Tadokoro S
    Nihon Rinsho; 2013 Apr; 71(4):684-8. PubMed ID: 23678600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
    Tadori Y; Forbes RA; McQuade RD; Kikuchi T
    Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aripiprazole: a new atypical antipsychotic drug].
    Fischer B; Davids E; Gastpar M
    Fortschr Neurol Psychiatr; 2004 Sep; 72(9):497-502. PubMed ID: 15365912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aripiprazole: does partial dopaminergic agonism translate into clinical benefits?
    Crismon ML; DeLeon A; Miller AL
    Ann Pharmacother; 2003 May; 37(5):738-40. PubMed ID: 12708954
    [No Abstract]   [Full Text] [Related]  

  • 5. Agitation associated with aripiprazole initiation.
    Lea JW; Stoner SC; Lafollette J
    Pharmacotherapy; 2007 Sep; 27(9):1339-42. PubMed ID: 17723088
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
    Gründer G; Kungel M; Ebrecht M; Göröcs T; Modell S
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S21-5. PubMed ID: 16508892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic.
    Keck PE; McElroy SL
    Expert Opin Investig Drugs; 2003 Apr; 12(4):655-62. PubMed ID: 12665420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
    Tadori Y; Kikuchi T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aripiprazole: pharmacology, efficacy, safety and tolerability.
    Kinghorn WA; McEvoy JP
    Expert Rev Neurother; 2005 May; 5(3):297-307. PubMed ID: 15938662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aripiprazole in the treatment of Alzheimer's disease.
    De Deyn PP; Drenth AF; Kremer BP; Oude Voshaar RC; Van Dam D
    Expert Opin Pharmacother; 2013 Mar; 14(4):459-74. PubMed ID: 23350964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A new approach to antischizophrenic therapeutics: D2 dopamine receptor partial agonists].
    Costentin J
    Ann Pharm Fr; 2009 Sep; 67(5):310-9. PubMed ID: 19695367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine partial agonists: a new class of antipsychotic.
    Lieberman JA
    CNS Drugs; 2004; 18(4):251-67. PubMed ID: 15015905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
    Kerpel-Fronius S; Lóránt M
    Neuropsychopharmacol Hung; 2004 Dec; 6(4):177-84. PubMed ID: 15825673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
    Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
    J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Focus on aripiprazole.
    Green B
    Curr Med Res Opin; 2004; 20(2):207-13. PubMed ID: 15006016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
    Leite JV; Guimarães FS; Moreira FA
    Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer.
    Narita M; Takei D; Shiokawa M; Tsurukawa Y; Matsushima Y; Nakamura A; Takagi S; Asato M; Ikegami D; Narita M; Amano T; Niikura K; Hashimoto K; Kuzumaki N; Suzuki T
    Eur J Pharmacol; 2008 Dec; 600(1-3):105-9. PubMed ID: 18955042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antipsychotic drug action: antagonism, inverse agonism or partial agonism.
    Strange PG
    Trends Pharmacol Sci; 2008 Jun; 29(6):314-21. PubMed ID: 18471899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole (Otsuka Pharmaceutical Co).
    Ozdemir V; Fourie J; Ozdener F
    Curr Opin Investig Drugs; 2002 Jan; 3(1):113-20. PubMed ID: 12054061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.